Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H30O3 |
Molecular Weight | 366.4932 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@]1([H])[C@@]3([H])[C@]4([H])[C@]5([H])C[C@]5([H])[C@@]6(CCC(=O)O6)[C@@]4(C)CC[C@]3([H])[C@@]7(C)CCC(=O)C=C27
InChI
InChIKey=METQSPRSQINEEU-HXCATZOESA-N
InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
Molecular Formula | C24H30O3 |
Molecular Weight | 366.4932 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7625729 | https://www.ncbi.nlm.nih.gov/pubmed/23530659 | https://www.ncbi.nlm.nih.gov/pubmed/7107766 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7625729 | https://www.ncbi.nlm.nih.gov/pubmed/23530659 | https://www.ncbi.nlm.nih.gov/pubmed/7107766 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf
Drospirenone (INN, USAN), also known as 1,2-dihydrospirorenone, is a steroidal progestin of the spirolactone group. Drospirenone binds strongly to the progesterone receptor (PR) and mineralocorticoid receptor (MR), with lower affinity, to the androgen receptor (AR), and very low affinity for the glucocorticoid receptor (GR). Drospirenone is an ingredient in some birth control pills and hormone replacement therapy. In combination with ethinylestradiol it is used as contraception, and for women who want contraception it is also approved by the U.S. Food and Drug Administration (FDA) to treat vasomotor symptoms due to menopause.It is sold as a combined oral contraceptive under the brand names Yasmin (US, EU, Latin America), Jasmine (France), Yarina (Russia) in a dosage containing drospirenone 3 mg/ethinylestradiol 30 µg. In the United States, Bayer Schering released a pill based on Yasmin with the B vitamin folate (B9), which is marketed under the names Safyral and Beyaz.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7107766
Curator's Comment: # Bayer HealthCare Pharmaceuticals
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729 |
|||
Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729 |
|||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | YASMIN Approved UseINDICATIONS AND USAGE. Yasmin is an estrogen/progestin COC indicated for use by women to prevent pregnancy Launch Date9.8953921E11 |
|||
Primary | Angeliq Approved UseIndications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Launch Date1.12777914E12 |
|||
Primary | Angeliq Approved UseIndications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Launch Date1.12777914E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
9.85 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
33.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
27 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
41 ng/mL |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1007 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
140 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
506 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
25.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
30 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
30 h |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4% |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Disc. AE: Premenstrual syndrome, Migraine headache... Other AEs: Premenstrual syndrome, Migraine headache... AEs leading to discontinuation/dose reduction: Premenstrual syndrome (6.7%) Other AEs:Migraine headache (1.5%) Premenstrual syndrome (13.2%) Sources: Migraine headache (10.7%) Breast discomfort (8.3%) Nausea and vomiting (4.5%) Abdominal discomfort (2.3%) Mood change (2.3%) |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Disc. AE: Weight gain, Headache... AEs leading to discontinuation/dose reduction: Weight gain (> 0.45) Sources: Headache (> 0.45) Depression (> 0.45) Menorrhagia (> 0.45) Skin disorder (> 0.45) Emotional lability (> 0.45) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Migraine headache | 1.5% Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Migraine headache | 10.7% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Premenstrual syndrome | 13.2% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Abdominal discomfort | 2.3% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Mood change | 2.3% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Nausea and vomiting | 4.5% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Premenstrual syndrome | 6.7% Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Breast discomfort | 8.3% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Depression | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Emotional lability | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Headache | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Menorrhagia | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Skin disorder | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Weight gain | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
minimum | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
minimum | |||
moderate [IC50 31200 uM] | no (co-administration study) Comment: "IC50 units given are ""mM""; no significant effect of DRSP on the systemic clearance of the CYP3A4 product omeprazole sulfone was found" Page: 25.0 |
|||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
moderate [IC50 36500 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
yes [IC50 14500 uM] | |||
yes [IC50 3390 uM] | no (co-administration study) Comment: "IC50 units given are ""mM""; daily oral administration of 3 mg DRSP for 14 days did not affect the oral clearance of omeprazole (40 mg, single oral dose) and the CYP2C19 product 5-hydroxy omeprazole" Page: 25.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
yes | no (co-administration study) Comment: simvastatin is not expected to affect DRSP's metabolism; When tested with midazolam, PK parameters of midazolam were similar regardless whether it was dosed with DSRP or with placebo. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins. | 1992 Dec |
|
New drugs 2002. Part II. | 2002 Apr |
|
Dutch GPs warned against new contraceptive pill. | 2002 Apr 13 |
|
Is [symbol: see text] Yasmin a "truly different" pill? | 2002 Aug |
|
Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. | 2002 Dec |
|
Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. | 2002 Dec |
|
Yasmin: the reason why. | 2002 Dec |
|
The renin-aldosterone system and drospirenone. | 2002 Feb |
|
Systematic optimisation of high-performance liquid chromatographic separation by varying the temperature, gradient, and stationary phase. | 2002 Jan |
|
A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. | 2002 Jan |
|
Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. | 2002 Nov |
|
Update and future of systemic acne treatment. | 2003 |
|
Classification and pharmacology of progestins. | 2003 Dec 10 |
|
Yasmin advert withdrawn--why and how. | 2003 Mar |
|
Androgens and antiandrogens. | 2003 Nov |
|
Hormone therapy and the cardiovascular system: the critical role of progestins. | 2003 Oct |
|
New progestogens: a review of their effects in perimenopausal and postmenopausal women. | 2004 |
|
Rationale for new oral contraceptive dosing. | 2004 Jan-Feb |
|
Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. | 2004 Jun |
|
Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. | 2004 Nov |
|
Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women. | 2004 Oct |
|
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. | 2005 Jan |
|
Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. | 2005 Nov-Dec |
|
Effects of drospirenone/estrogen combinations on bone metabolism. | 2005 Oct |
|
Added benefits of drospirenone for compliance. | 2005 Oct |
|
Gateways to clinical trials. | 2005 Sep |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf
To prevent pregnancy: One tablet (containing 3 mg drospirenone and 0.03 mg ethinyl estradiol) daily by mouth at the same time every day.
To prevent symptoms due to menopause. one tablet (0.25 mg drospirenone/0.5 mg ethinyl estradiol) taken by mouth once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729
Activity of drospirenone was investigated by transiently transfecting the human MR (pRShMR) and pMMTV-CAT into COS 1 cells. Cells were treated with 10 nmol/l aldosterone and, in addition, with increasing amounts of the drospirenone (1nM – 1 mkM). After 48 hrs cells were harvested and duplicate dishes were assayed for activity
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:02:01 UTC 2023
by
admin
on
Sat Dec 16 18:02:01 UTC 2023
|
Record UNII |
N295J34A25
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G03AC10
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
||
|
WHO-ATC |
G03AA12
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
||
|
NDF-RT |
N0000011301
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
||
|
NDF-RT |
N0000175602
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
||
|
LIVERTOX |
333
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
||
|
WHO-ATC |
G03FA17
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
||
|
NCI_THESAURUS |
C776
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
||
|
WHO-VATC |
QG03FA17
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
||
|
WHO-VATC |
QG03AA12
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6519
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
11636
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | RxNorm | ||
|
50838
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
1229409
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
C47502
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
67392-87-4
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
760103
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
Drospirenone
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
N295J34A25
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
2874
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
SUB06413MIG
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
m4772
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | Merck Index | ||
|
N295J34A25
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
Drospirenone
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
DTXSID7046465
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
68873
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
266-679-2
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
DB01395
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
100000092375
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
JJ-45
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
7896
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
968
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
C035144
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY | |||
|
CHEMBL1509
Created by
admin on Sat Dec 16 18:02:01 UTC 2023 , Edited by admin on Sat Dec 16 18:02:01 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE INACTIVE -> PARENT |
MAJOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
at 195 nm
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |